Pattern of Antimicrobial Resistance to Escherichia Coli Among the Urinary Tract Infection Patients in Bangladesh

G. Acherjya, K. Tarafder, R. Ghose, D. Islam, M. Ali, N. Akhtar, R. Chakrabortty, S. R. Sutradhar
{"title":"Pattern of Antimicrobial Resistance to Escherichia Coli Among the Urinary Tract Infection Patients in Bangladesh","authors":"G. Acherjya, K. Tarafder, R. Ghose, D. Islam, M. Ali, N. Akhtar, R. Chakrabortty, S. R. Sutradhar","doi":"10.11648/J.AJIM.20180605.17","DOIUrl":null,"url":null,"abstract":"Urinary Tract Infection (UTI) is very common in our day-to-day clinical practice. Among all the organisms Escherichia coli (E coli) is the most common but antimicrobial resistance becomes an alarming issue for UTI management now a days. Aim of this study is to assess the pattern of antimicrobial resistance to E coli among the UTI patients in Jashore, Bangladesh. This observational study was conducted from February, 2017 to January, 2018 in the district of Jashore, Bangladesh. We recruited 696 patients of both sex with UTI only infected by E coli. We had excluded the patients with UTI caused by other than E coli, female during menstruation, pregnancy, history of taking antibiotics within last 21 days, catheterization within 1 month and pelvic organ & genito urinary tract surgery within 6 months. Evaluation of antimicrobial resistance was done according to the standard bacteriological methods. Mean age of our study cases was 41.46±17.21 years with the range from 15 to 91 years. More than 85% participants were female with a sex ratio was 8:1.5. Reproductive age group ranged from 21 to 50 years was affected most commonly which constituted approximately two-third of our study. Our study revealed that the maximum antimicrobial resistance to E coli was Cotrimoxazole (95.0%), followed by Ceftazidime (75.7%), Gentamicin (70.3%), Amikacin (69.0%), Imipenam (58.9 %,), Cefixime (58.0%), Ciprofloxacin (57.3%), Azithromycin (56.0%), Cefuroxime (46.6%), Cefotaxime (37.4%), Ceftriaxone (35.2%), Meropenem (32.2%), Nitrofurantion (4.7%). With the high magnitude of antimicrobial resistance to E coli among the UTI patients even with extended generation of Cephalosporins, Carbapenams, Ciprofloxacin, Cotrimoxazole, Azithromycin and Aminoglycosides, our recommendation as first line empirical treatment option in UTI should be Nitrofurantoin due to low resistance pattern.","PeriodicalId":7179,"journal":{"name":"Advanced Biomedicine","volume":"25 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Biomedicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11648/J.AJIM.20180605.17","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

Urinary Tract Infection (UTI) is very common in our day-to-day clinical practice. Among all the organisms Escherichia coli (E coli) is the most common but antimicrobial resistance becomes an alarming issue for UTI management now a days. Aim of this study is to assess the pattern of antimicrobial resistance to E coli among the UTI patients in Jashore, Bangladesh. This observational study was conducted from February, 2017 to January, 2018 in the district of Jashore, Bangladesh. We recruited 696 patients of both sex with UTI only infected by E coli. We had excluded the patients with UTI caused by other than E coli, female during menstruation, pregnancy, history of taking antibiotics within last 21 days, catheterization within 1 month and pelvic organ & genito urinary tract surgery within 6 months. Evaluation of antimicrobial resistance was done according to the standard bacteriological methods. Mean age of our study cases was 41.46±17.21 years with the range from 15 to 91 years. More than 85% participants were female with a sex ratio was 8:1.5. Reproductive age group ranged from 21 to 50 years was affected most commonly which constituted approximately two-third of our study. Our study revealed that the maximum antimicrobial resistance to E coli was Cotrimoxazole (95.0%), followed by Ceftazidime (75.7%), Gentamicin (70.3%), Amikacin (69.0%), Imipenam (58.9 %,), Cefixime (58.0%), Ciprofloxacin (57.3%), Azithromycin (56.0%), Cefuroxime (46.6%), Cefotaxime (37.4%), Ceftriaxone (35.2%), Meropenem (32.2%), Nitrofurantion (4.7%). With the high magnitude of antimicrobial resistance to E coli among the UTI patients even with extended generation of Cephalosporins, Carbapenams, Ciprofloxacin, Cotrimoxazole, Azithromycin and Aminoglycosides, our recommendation as first line empirical treatment option in UTI should be Nitrofurantoin due to low resistance pattern.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
孟加拉国尿路感染患者对大肠埃希菌的耐药性模式
尿路感染(UTI)在我们的日常临床实践中非常常见。在所有的微生物中,大肠杆菌(大肠杆菌)是最常见的,但抗菌素耐药性现在成为尿路感染管理的一个令人担忧的问题。本研究的目的是评估孟加拉国j岸上尿路感染患者对大肠杆菌的耐药性模式。这项观察性研究于2017年2月至2018年1月在孟加拉国Jashore地区进行。我们招募了696例仅感染大肠杆菌的男女尿路感染患者。排除非大肠杆菌所致尿路感染、女性经期、孕期、21天内使用抗生素史、1个月内导尿、6个月内盆腔器官及生殖器尿路手术患者。按照标准细菌学方法进行耐药性评价。我们研究病例的平均年龄为41.46±17.21岁,年龄范围为15 ~ 91岁。超过85%的参与者是女性,性别比例为8:1.5。21至50岁的生育年龄组最常见,约占我们研究的三分之二。结果显示,大肠杆菌对抗生素的耐药率最高的是复方新诺明(95.0%),其次是头孢他啶(75.7%)、庆大霉素(70.3%)、阿米卡星(69.0%)、亚胺培南(58.9%)、头孢克肟(58.0%)、环丙沙星(57.3%)、阿奇霉素(56.0%)、头孢呋辛(46.6%)、头孢噻肟(37.4%)、头孢曲松(35.2%)、美罗培南(32.2%)、硝基呋喃(4.7%)。由于长期使用头孢菌素、碳青霉南类、环丙沙星、复方新诺明、阿奇霉素和氨基糖苷类药物的UTI患者对大肠杆菌的耐药程度较高,我们推荐呋喃托因作为UTI的一线经验治疗方案,因为其耐药模式较低。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
DEBRIDEMENT IN DIABETIC FOOT ULCER Malnutrition in Patients Following Bariatric Surgery Cardiac Diseases During Systemic Inflammatory Diseases in the Internal Medicine and Medical Oncology Department of NTHC-HKM of Cotonou Blood Count Under the Effect of Erythropoietin (EPO) in Patients with Chronic Hemodialysis Increased Colorectal Cancer Rate in Turner Syndrome: A Case Control Study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1